1,2,3,4-四氢-6-羟基异喹啉-3-羧酸 | 76824-99-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 1,2,3,4-四氢-6-羟基异喹啉-3-羧酸
• 中文别名: (±)-6-羟基-1,2,3,4-四氢-异喹啉-3-羧酸
• 英文名称: 6-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
• 英文别名: 6-hydroxy-1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid；6-Hydroxy-1,2,3,4-tetrahydroisoquinolin-2-ium-3-carboxylate；6-hydroxy-1,2,3,4-tetrahydroisoquinolin-2-ium-3-carboxylate
• CAS: 76824-99-2
• 化学式: C₁₀H₁₁NO₃
• mdl: MFCD00800582
• 分子量: 193.202
• InChiKey: CRAGDYRHPWTZJL-UHFFFAOYSA-N

物化性质

• 沸点：
  456.3±45.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-6-羟基异喹啉-3-羧酸 在 吡啶 、 盐酸 、 sodium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.08h， 生成 2-Diphenylacetyl-6-hydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid
  参考文献：
  名称：

  A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site

  摘要：

  The availability of peptide and non-peptide Ang II receptor antagonists has permitted the study of Ang II receptor heterogeneity. It is now widely recognized that there are at least two distinct Ang II receptor subtypes. AT(1) receptors are selective in their recognition of agents such as losartan, DuP 532, L-158,809, SK&F108566, and similar non-peptides. To date, all of the well-known actions of Ang II in mammals are blocked by the AT(1) selective antagonists such as losartan and are thus designated as being mediated by the AT(1) receptor. Although there have been reports of functional activity mediated through AT(2) sites, the pharmacological role for the AT(2) receptor has not yet been elucidated. Herein, we report the chemistry and SAR on a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids which have selective affinity for AT(2) receptors. The most potent of which (19) has an IC50 Of 30 nM for the AT(2) receptor in the rat adrenal radioligand binding assay.

  DOI：

  10.1021/jm00077a001
• 作为产物：
  描述：

  6-甲氧基-1,2,3,4-四氢异喹啉-3-羧酸 以86%的产率得到
  参考文献：
  名称：

  MIYAKE, AKIO;ITOH, KATSUMI;AONO, TETSUYA;KISHIMOTO, SHOJI;MATSUSHITA, YOS+, J. TAKEDA RES. LAB., 1984, 43, N 3-4, 53-76

  摘要：

  DOI：

文献信息

• Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
  申请人：SENOMYX, INC.

  公开号：US09247759B2

  公开（公告）日：2016-02-02

  The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.

  本发明涉及发现，T2R味觉受体家族中的特定人类味觉受体对存在于咖啡等物质中的特定苦味化合物产生反应。此外，本发明涉及发现特定化合物和含有该化合物的组合物，其作为苦味阻断剂的功能，以及将其用作苦味阻断剂或调味剂，例如在咖啡和咖啡味食品、饮料和药品中。此外，本发明涉及发现一种对多种不同人类T2R产生拮抗作用的化合物，以及将其用于检测中和作为人类和动物摄入的组合物中的苦味阻断剂。
• [EN] PYRAZOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION<br/>[FR] DÉRIVÉS DE PYRAZOLE INHIBANT LA PRODUCTION DE LEUCOTRIÈNE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014014874A1

  公开（公告）日：2014-01-23

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其中A1、A2、L1和B如本文所定义。式（I）的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式（I）的化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• [EN] IAP ANTAGONISTS<br/>[FR] ANTAGONISTES D'IAP
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013192286A1

  公开（公告）日：2013-12-27

  There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

  已披露调节凋亡抑制剂（IAPs）活性的化合物，包含该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病和失调凋亡疾病（如癌症）的方法。
• [EN] MODULATORS OF REV-ERB<br/>[FR] MODULATEURS DE REV-ERB
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015103527A1

  公开（公告）日：2015-07-09

  The subject matter herein concerns the identification and development of potent synthetic REV-ERB ligands, such as in vivo agonists and antagonists. These compounds allow for characterization of the effects of modulation of this receptor in vivo specifically on circadian behavior and metabolism, and have suitable characteristics for development of medicinal compounds useful for treatment of malconditions such as diabetes, obesity, atherosclerosis, dyslipidemia, a circadian rhythm disorder, coronary artery disease, bipolar disorder, depression, cancer, a sleep disorder, an anxiety disorder, an addiction disorder, a bone-related disorder such osteoporosis, a skeletal muscle disease, e.g., with compromised exercise capacity, or an autoimmune disorder such as psoriasis, multiple sclerosis, inflammatory bowel disease, and others.

  本文涉及识别和开发强效合成REV-ERB配体，例如体内激动剂和拮抗剂。这些化合物可用于特定在体内对昼夜节律行为和新陈代谢的调节效果进行表征，并具有适合开发用于治疗糖尿病、肥胖症、动脉粥样硬化、血脂异常、昼夜节律紊乱、冠状动脉疾病、躁郁症、抑郁症、癌症、睡眠障碍、焦虑障碍、成瘾障碍、骨相关疾病如骨质疏松症、骨骼肌肉疾病（例如，运动能力受损）、自身免疫性疾病如牛皮癣、多发性硬化、炎症性肠病等疾病的药用化合物的特性。
• [EN] TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS<br/>[FR] COMPOSES DE TETRAHYDROISOQUINOLINE OU D'ISOCHROMAN EN TANT QUE LIGANDS DU RECEPTEUR ORL-1 POUR LE TRAITEMENT DE LA DOULEUR ET DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：PFIZER JAPAN INC

  公开号：WO2005016913A1

  公开（公告）日：2005-02-24

  This invention provides the compounds of formula (I), or its a pharmaceutically acceptable ester or amide of such compound, or a pharmaceutically acceptable salt thereof, wherein X1 is NH; R1, R2, R4 through R6 and R7 through R11 are all hydrogen; R3 is hydroxy; X2 and X3 are methylene; X4 is a bond; and X5 is a carbon atom, and the like. These compounds have ORLI -receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  这项发明提供了式（I）的化合物，或其药学上可接受的酯或酰胺，或其药学上可接受的盐，其中X1为NH；R1、R2、R4至R6和R7至R11均为氢；R3为羟基；X2和X3为亚甲基；X4为键；X5为碳原子等。这些化合物具有ORLI-受体拮抗活性；因此，可用于治疗疼痛、各种中枢神经系统疾病等疾病或症状。